The pharmaceutical company said the data collection for this update was completed before the delta variant emerged in the United States.
“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” said Stephane Bancel, chief executive officer of Moderna.
Moderna booster candidates demonstrated robust antibody responses to COVID-19 variants of concern, including delta, the company said.
Bancel said Moderna is working toward developing a single-dose annual booster that provides protection against COVID, flu and RSV for adults.
This is a developing story; check back for updates.
Copyright © 2021 WLS-TV. All Rights Reserved.